SU9516 is a 3-substituted indolinone compound displaying anti-proliferative and proapoptotic properties in tumor cells. SU9516 displays activity as a selectively potent ATP-competitive inhibitor of CDKs. It also shows no significant effect (IC50 >10 μM) on the activities of PKC, p38, PDGFRβ, or EGFR. SU9516 has an Inhibitory effect on proliferation of growth-factor stimulated colon carcinoma cells by binding to Cdk2 and preventing the phosphorylation of pRb and its dissociation from E2F. SU9516 is an inhibitor of Cdc2, Cdk2 and Cdk4.
1. Lane, M E., et al., 2001. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer research. 61(16): 6170-7. PMID: 11507069
2. Yu, Bo., et al., 2002. SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells. Biochemical pharmacology. 64(7): 1091-100. PMID: 12234612
Ver como otros han utilizado SU9516 (CAS 666837-93-0). Haga click en la entrada de PubMed .
PMID: # 25394488 Su, M. et al. 2015. Cell Death Differ. 22: 986-99.
PMID: # 24101496 Bogdanow, et al. 2013. Proc Natl Acad Sci U S A. 110: 17510-5.
PMID: # 20844576 Zydek, M. et al. 2010. PLoS Pathog. 6: -.
PMID: # 31740384 Pharmacol. Res. 104545.